Depomed, Inc. (NASDAQ: DEPO), a specialty pharmaceutical company, is devoted to enhancing existing pharmaceutical products. To date, the company has brought two products to market and has developed a pipeline with late-stage product opportunities designed to address common medical conditions. Depomed’s core delivery technology, AcuForm, is a patented, polymer-based technology that improves delivery through gastric retention. For further information, visit the Company’s web site at www.depomedinc.com.
- 17 years ago
QualityStocks
Depomed, Inc. (NASDAQ: DEPO)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Delivers Critical Security and Defense Solutions to Governments and Organizations
Safe Pro Group delivers AI, drone-based services, and ballistic protective gear, to customers in the…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…